UNLABELLED: (153)Sm-ethylenediamine tetramethylene phosphonic acid ((153)Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of (153)Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. METHODS: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of (153)Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of (153)Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after (153)Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. RESULTS: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5% of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). CONCLUSION: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.
UNLABELLED: (153)Sm-ethylenediamine tetramethylene phosphonic acid ((153)Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of (153)Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. METHODS: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of (153)Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of (153)Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after (153)Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. RESULTS: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5% of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). CONCLUSION: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.
Authors: Mónica Coronado; Andrés Redondo; Juan Coya; Enrique Espinosa; Rosa M Couto; Pilar Zamora; Maria Dolores Marin; Beatriz Castelo; Maria Eugenia Lillo; Laura Frutos; Manuel González Barón; Luis M Martín Curto Journal: Clin Nucl Med Date: 2006-10 Impact factor: 7.794
Authors: Robert F Hobbs; Todd McNutt; Sébastien Baechler; Bin He; Caroline E Esaias; Eric C Frey; David M Loeb; Richard L Wahl; Ori Shokek; George Sgouros Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038
Authors: J F Eary; C Collins; M Stabin; C Vernon; S Petersdorf; M Baker; S Hartnett; S Ferency; S J Addison; F Appelbaum Journal: J Nucl Med Date: 1993-07 Impact factor: 10.057
Authors: David M Loeb; Elizabeth Garrett-Mayer; Robert F Hobbs; Andrew R Prideaux; George Sgouros; Ori Shokek; Moody D Wharam; Tammy Scott; Cindy L Schwartz Journal: Cancer Date: 2009-06-01 Impact factor: 6.860
Authors: Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros Journal: J Nucl Med Date: 2007-05-15 Impact factor: 10.057
Authors: Wolfgang Kainz; Esra Neufeld; Wesley E Bolch; Christian G Graff; Chan Hyeong Kim; Niels Kuster; Bryn Lloyd; Tina Morrison; Paul Segars; Yeon Soo Yeom; Maria Zankl; X George Xu; Benjamin M W Tsui Journal: IEEE Trans Radiat Plasma Med Sci Date: 2019-01
Authors: Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz Journal: Cancer Biother Radiopharm Date: 2018-10-23 Impact factor: 3.099
Authors: Lidia Strigari; Mark Konijnenberg; Carlo Chiesa; Manuel Bardies; Yong Du; Katarina Sjögreen Gleisner; Michael Lassmann; Glenn Flux Journal: Eur J Nucl Med Mol Imaging Date: 2014-06-11 Impact factor: 9.236
Authors: Donika Plyku; David M Loeb; Andrew R Prideaux; Sébastien Baechler; Richard L Wahl; George Sgouros; Robert F Hobbs Journal: Cancer Biother Radiopharm Date: 2015-11 Impact factor: 3.099
Authors: Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz Journal: Cancer Biother Radiopharm Date: 2018-04-25 Impact factor: 3.099